0000899243-18-017243.txt : 20180619
0000899243-18-017243.hdr.sgml : 20180619
20180619190614
ACCESSION NUMBER: 0000899243-18-017243
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180619
FILED AS OF DATE: 20180619
DATE AS OF CHANGE: 20180619
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dallas Jayson Donald Alexander
CENTRAL INDEX KEY: 0001650322
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37519
FILM NUMBER: 18908339
MAIL ADDRESS:
STREET 1: AIMMUNE THERAPEUTICS, INC.
STREET 2: 8000 MARINA BOULEVARD, SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aimmune Therapeutics, Inc.
CENTRAL INDEX KEY: 0001631650
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452748244
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
BUSINESS PHONE: (650) 614-5220
MAIL ADDRESS:
STREET 1: 8000 MARINA BOULEVARD
STREET 2: SUITE 300
CITY: BRISBANE
STATE: CA
ZIP: 94005-1884
FORMER COMPANY:
FORMER CONFORMED NAME: Allergen Research Corp
DATE OF NAME CHANGE: 20150123
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-06-19
0
0001631650
Aimmune Therapeutics, Inc.
AIMT
0001650322
Dallas Jayson Donald Alexander
C/O AIMMUNE THERAPEUTICS, INC.
8000 MARINA BOULEVARD, SUITE 300
BRISBANE
CA
94005-1884
1
1
0
0
President and CEO
Common Stock, $0.0001 par value
2018-06-19
4
A
0
60000
0.00
A
60000
D
Stock Option (right to buy)
30.68
2018-06-19
4
A
0
350000
0.00
A
2028-06-19
Common Stock
350000
350000
D
These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from June 19, 2018, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 19, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
/s/ Douglas T. Sheehy, as Attorney-in-Fact for Jayson Donald Alexander Dallas
2018-06-19